To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Strengthens the use of patient-experience data within the benefit-risk framework for approval of new drugs. The main policy areas are Health.
Who Benefits and How
The main beneficiaries are the people, organizations, or agencies identified in the bill's substantive provisions.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Strengthens the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
Strengthens the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Key Policy Areas
Health
Primary Purpose
Strengthens the use of patient-experience data within the benefit-risk framework for approval of new drugs.
Policy Domains
Sponsors
Legislative Progress
IntroducedMr. Wicker (for himself and Ms. Klobuchar) introduced the following …
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology